47 results
8-K
EX-99.1
SWKH
Swk Holdings Corp
22 Mar 24
1 Collaborative Approach to Life Science Financing Shareholder Presentation March 2024
3:21pm
; investment generated a 2.4x CoC return Narcan is the only FDA approved, intranasal Naloxone product for the treatment of opioid overdose Narcan
8-K
EX-99.1
SWKH
Swk Holdings Corp
17 May 23
Regulation FD Disclosure
8:00am
is the only FDA approved, intranasal Naloxone product for the treatment of opioid overdose Narcan is appropriately priced with revenue growth from expanded
8-K
EX-99.1
SWKH
Swk Holdings Corp
4 Apr 23
Regulation FD Disclosure
5:14pm
economics for $2.5mm; Investment generated a 2.4x CoC return Narcan is the only FDA approved, intranasal Naloxone product for the treatment of opioid
8-K
EX-99.1
nrodxzwet91jg0x8b
17 Aug 22
Regulation FD Disclosure
4:05pm
8-K
EX-99.1
0v11lusj5bfxl
17 May 22
Regulation FD Disclosure
5:46pm
8-K
EX-99.1
q8bucc5ayoyhuq5gexp
28 Mar 22
Regulation FD Disclosure
7:42pm
8-K
EX-99.1
6eqs0bm
23 Nov 21
Regulation FD Disclosure
7:00am
8-K
EX-99.1
sy2lkkbf z1
8 Sep 21
Regulation FD Disclosure
5:17pm
8-K
EX-99.1
517ehoni
19 Jul 21
SWK Holdings Provides Portfolio Update Highlighting Recent Achievements
8:00am
8-K
EX-99.1
6f38ax5d1hxy
20 May 21
Regulation FD Disclosure
12:00am
8-K
EX-99.1
o02kg3z534jj2gu9
2 Apr 21
Regulation FD Disclosure
8:00am